Yaw Opoku-Damoah

Dr. Yaw Opoku-Damoah

Australian Institute for Bioengineering & Nanotechnology, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SKSamuel Kesse
Samuel Kesse
KBKofi Boakye-Yiadom
Kofi Boakye-Yiadom
BOBelynda Owoya Ochete
Belynda Owoya Ochete
YOYaw Opoku-Damoah
Yaw Opoku-Damoah
FAFahad Akhtar
Fahad Akhtar
BWBo Wang
Bo Wang
Mesoporous silica nanomaterials (MSNs) have made remarkable achievements and are being thought of by researchers as materials that can be used to effect great change in cancer therapies, gene delivery, and drug delivery because of their optically transparent properties, flexible size, functional surface, low toxicity profile, and very good drug loading competence. Mesoporous silica nanoparticles (MSNPs) show a very high loading capacity for therapeutic agents. It is well known that cancer is one of the most severe known medical conditions, characterized by cells that grow and spread rapidly. Thus, curtailing cancer is one of the greatest current challenges for scientists. Nanotechnology is an evolving field of study, encompassing medicine, engineering, and science, and it has evolved over the years with respect to cancer therapy. This review outlines the applications of mesoporous nanomaterials in the field of cancer theranostics, as well as drug and gene delivery. MSNs employed as therapeutic agents, as well as their importance and future prospects in the ensuing generation of cancer theranostics and drug and therapeutic gene delivery, are discussed herein. Thus, the use of mesoporous silica nanomaterials can be seen as using one stone to kill three birds.